ArticleLeukemia2020
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed.
- Prognostic Significance of Secondary-Type Mutations in NPM1-Mutated Acute Myeloid Leukemia.Cancer medicine · 2026Article
- NPM1-rearranged AML: clinical features, molecular pathogenesis, and therapeutic perspectives.International journal of hematology · 2026Review
- Clinical Characteristics, Gene Mutation Profiles and Prognosis of Patients With Acute Myeloid Leukemia Carrying PHF6 Mutations.Cancer medicine · 2026Article
- [Analysis of risk factors for early death in NPM1-mutated acute myeloid leukemia patients].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.Blood neoplasia · 2026Article
- Article
- Article
- Review
- Article
- Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.Frontiers in pharmacology · 2025Review
- Acute Myeloid Leukemia with Normal Cytogenetics andBiomedicines · 2024Article
- [Clinical characteristics and treatment efficacy of newly diagnosed acute leukemia in the plateau].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.Innovation (Cambridge (Mass.)) · 2024Article
- Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients.Cancer medicine · 2024Article
- Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia.Blood cancer journal · 2024Article
- Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia.Biomarker research · 2024Review
- Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.Blood advances · 2024Article
- Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.Blood cancer discovery · 2024Review
- Prognostic impact ofTherapeutic advances in hematology · 2024Article
- Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) have become an important tool to assess patients' prognosis and guide treatment. We tested the prognostic impact of the 2017 ELN classification in a large cohort of 863 AML patients aged <60 years similarly treated on Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology studies. Based on multivariable models within each ELN genetic-risk group, we identified additional gene mutations that may refine the 2017 ELN risk classification. BCOR- or SETBP1-mutated favorable-risk patients with non-core-binding factor AML and IDH-mutated adverse-risk patients had intermediate-risk outcomes. Outcomes of NPM1/WT1 co-mutated patients and those of ZRSR2-mutated patients resembled outcome of adverse-risk patients. Moreover, FLT3-ITD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.